Document:

Document

Exhibit 10.1                                                                                                         EXECUTION VERSION 

SEVENTH AMENDMENT TO 
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT

THIS SEVENTH AMENDMENT TO THE AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”), is made as of November 18, 2021, by and among Oaktree Specialty Lending Corporation, as the collateral manager (together with its permitted successors and assigns, the “Collateral Manager”), OCSL Senior Funding II LLC, as the borrower (the “Borrower”), Citibank, N.A., as administrative agent (the “Administrative Agent”) and Citibank, N.A., as the sole lender (the “Lender”).
RECITALS
    WHEREAS, the Collateral Manager, Oaktree Specialty Lending Corporation, as the seller (together with its permitted successors and assigns, the “Seller”), the Borrower, the Administrative Agent, the Lender and Wells Fargo Bank, National Association, as Collateral Agent, are parties to that certain Amended and Restated Loan and Security Agreement, dated as of January 31, 2018 (as the same has been previously amended and may be amended, modified, waived, supplemented, restated or replaced from time to time, the “Loan and Security Agreement”);  
    WHEREAS, pursuant to Section 13.1 of the Loan and Security Agreement, the Collateral Manager and the Borrower desire to, and have requested that the Administrative Agent agree to, amend certain provisions of the Loan and Security Agreement as provided herein; 
    WHEREAS, subject to the terms and conditions of this Amendment, the Administrative Agent and Lenders constituting at least the Required Lenders are willing to agree to such amendments to the Loan and Security Agreement. 
NOW THEREFORE, in consideration of the premises and the mutual covenants hereinafter contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1.Defined Terms.  Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed thereto in the Loan and Security Agreement.
2.Amendments.  The parties to the Loan and Security Agreement agree, effective as of the date set forth above, subject to the terms and conditions set forth herein and in reliance on the representations, warranties, covenants and agreements contained herein, that the Loan and Security Agreement is hereby amended to delete the stricken text (indicated textually in the same manner as the following example: stricken text) and to add the bold and double-underlined text (indicated textually in the same manner as the following example: bold and underlined text) as set forth on the pages of the Loan and Security Agreement attached as Exhibit A hereto. 
3.Conditions to Effectiveness. This Amendment shall become effective as of the date first written above upon the satisfaction of each of the following conditions:
(A)the execution and delivery of this Amendment by each party hereto;

(B)the Borrower has delivered legal opinions of Milbank LLP, each dated as of the date hereof, covering the same matters as the legal opinions provided by Milbank LLP on the Closing Date;

1
33560.00031

(C)the Administrative Agent’s receipt of a good standing certificate for the Borrower and the Collateral Manager issued by the applicable office body of its jurisdiction of organization and a certified copy of the resolutions of the board of managers or directors (or similar items) of the Borrower and the Collateral Manager approving this Amendment and the transactions contemplated hereby, certified by its secretary or other authorized officer; 

(D)UCC filings in order for the Collateral Agent to continue to have a valid, legal and perfected security interest in all of the Collateral; and 

(E)payment of all fees due on or prior to the date of this Amendment.

4.Representations and Warranties. The Borrower hereby represents and warrants that, as of the date first written above, (i) no Event of Default or Default has occurred and is continuing and (ii) the representations and warranties of the Borrower contained in the Loan and Security Agreement are true and correct in all material respects on and as of such day (other than any representation and warranty that is made as of a specific date).
5.Reaffirmation.  Except to the extent expressly amended by this Amendment, the terms and conditions of the Loan and Security Agreement and other Transaction Documents shall remain in full force and effect.  Each of the Transaction Documents, including the Loan and Security Agreement, and any and all other agreements, documents or instruments now or hereafter executed and/or delivered pursuant to the terms hereof or pursuant to the terms of the Loan and Security Agreement as amended hereby, are hereby amended so that any reference in such Transaction Documents to the Loan and Security Agreement, whether direct or indirect, shall mean a reference to the Loan and Security Agreement as amended hereby.  This Amendment shall constitute a Transaction Document under the Loan and Security Agreement.  
6.Miscellaneous.      This Amendment may be executed in counterparts, each of which shall be and all of which, when taken together, shall constitute one binding agreement.  The Article and/or Section headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purpose.  THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

[SIGNATURE PAGE FOLLOWS]
2

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their duly authorized representatives, all as of the day, month and year first above written.
                        
                        BORROWER

OCSL SENIOR FUNDING II LLC 

By: Oaktree Specialty Lending Corporation 
Its:  Designated Manager 

By:  Oaktree Fund Advisors, LLC 
Its:  Investment Advisor 

By:    /s/ Matthew Stewart_________    
Name: Matthew Stewart
Title: Senior Vice President

By:    /s/ Mary Gallegly___________    
Name: Mary Gallegly
Title: Senior Vice President

[SIGNATURES CONTINUE ON FOLLOWING PAGE]

[Signtature page to Seventh Amendment]

COLLATERAL MANAGER:

OAKTREE SPECIALTY LENDING CORPORATION

By:  Oaktree Fund Advisors, LLC
Its:   Investment Adviser

By: /s/ Matthew Stewart__________
Name: Matthew Stewart
Title: Senior Vice President

By: /s/ Mary Gallegly ____________
Name: Mary Gallegly
Title: Senior Vice President

[Signtature page to Seventh Amendment]

THE ADMINISTRATIVE AGENT:
CITIBANK, N.A.

By:  /s/ Vincent Nocerino____
Name: Vincent Nocerino
Title: Attorney in Fact

LENDER:

CITIBANK, N.A.,
By:  /s/ Vincent Nocerino____
Name: Vincent Nocerino 
Title: Attorney in Fact

[Signtature page to Seventh Amendment]

EXHIBIT A

Changes to the Loan and Security Agreement

[see attached]

Execution Version - Conformed through the Sixth Seventh Amendment
For informational purposes only

			
	$150,000,000200,000,000

AMENDED AND RESTATED

LOAN AND SECURITY AGREEMENT

by and among

OAKTREE SPECIALTY LENDING CORPORATION,
(Collateral Manager)

OCSL SENIOR FUNDING II LLC,
(Borrower)

OAKTREE SPECIALTY LENDING CORPORATION,
(Seller)

EACH OF THE LENDERS FROM TIME TO TIME PARTY HERETO,
(Lenders)

CITIBANK, N.A.,
(Administrative Agent)

and

WELLS FARGO BANK, NATIONAL ASSOCIATION,
(Collateral Agent)

Dated as of January 31, 2018

127235744v1

“Expense Reserve Account Amount”:  At any time, an amount equal to $50,000 minus the available balance of the Expense Reserve Account at such time.
“Facility Amount”:  Initially the Maximum Facility Amount, as such amount may vary from time to time pursuant to Section 2.3 hereof; provided that on or after the Reinvestment Period End Date, the Facility Amount shall mean the Advances Outstanding.
“Facility Maturity Date”:  JulyNovember 18, 2024 (or, if such day is not a Business Day, the next succeeding Business Day).
“FATCA”:  Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the Code.
“FDIC”:  The Federal Deposit Insurance Corporation, and any successor thereto.
“Federal Funds Rate”:  For any period, a fluctuating interest per annum rate equal, for each day during such period, to the weighted average of the overnight federal funds rates as reported in Federal Reserve Board Statistical Release H.15(519) or any successor or substitute publication selected by the Administrative Agent (or, if such day is not a Business Day, for the next preceding Business Day), or, if for any reason such rate is not available on any day, the rate determined, in the sole discretion of the Administrative Agent, to be the rate at which overnight federal funds are being offered in the national federal funds market at 9:00 a.m. on such day.
“Fee Letter”:  The Fee Letter, dated as of the date hereof, from Borrower to the Administrative Agent and the Lenders, and acknowledged by the Collateral Manager, as the same may be amended, restated, modified or supplemented from time to time.
“Fees”:  All fees required to be paid by the Borrower pursuant to this Agreement and the Fee Letter.
“Financial Asset”:  The meaning specified in Section 8-102(a)(9) of the UCC.
“Financial Sponsor”:  Any Person, including any Subsidiary of such Person, whose principal business activity is acquiring, holding, and selling investments (including controlling interests) in otherwise unrelated companies that each are distinct legal entities with separate management, books and records and bank accounts, whose operations are not integrated with one another and whose financial condition and creditworthiness are independent of the other companies so owned by such Person.
“First-Lien Broadly Syndicated Loan”:  Any First Lien Loan that is a Broadly Syndicated Loan.
of the Borrower or the Collateral Manager to perform its respective obligations under any Transaction Document to which it is a party, or (f) the status, existence, perfection, priority or enforceability of the Collateral Agent’s Lien on the Collateral.

“Material Modification”:  Any amendment or waiver of, or modification or supplement to, an Underlying Instrument governing an Eligible Loan executed or effected on or after the date on which such Loan is transferred to the Borrower, that:
(a)extends or delays the stated maturity date of such Loan;
(b)waives one or more interest payments, reduces the amount of interest due with respect to such Loan, reduces the rate at which interest accrues with respect to such Loan, reduces the portion of such Loan on which interest accrues, or permits any interest due in cash to be deferred or capitalized and added to the principal amount of such Loan (other than any deferral or capitalization already allowed by the terms of the Underlying Instruments of such Loan for performing credits under a re-pricing grid contained in the Underlying Instruments as of the Cut-Off Date);
(c)contractually or structurally subordinates such Loan by operation of a priority of payments, turnover provisions, the transfer of assets in order to limit recourse to the related Obligor or the granting of Liens (other than Permitted Liens) on any of the Underlying Assets securing such Loan;
(d)modifies, terminates, substitutes, alters or releases (other than as permitted by such Underlying Instruments) the Underlying Assets securing such Loan, and each such modification, termination, substitution, alteration or release, as determined in the sole reasonable discretion of the Controlling Lender, materially and adversely affects the value of such Loan;
(e)amends, waives, forbears, supplements or otherwise modifies in any way the definition of “Permitted Lien”, “Net Senior Leverage Ratio” or “Cash Interest Coverage Ratio” (or any respective comparable definitions in its Underlying Instruments) or the definition of any component thereof in a manner that, in the sole reasonable discretion of the Controlling Lender, is materially adverse to any Lender; or
(f)reduces or forgives any or all of the principal amount due under such Loan.
“Maximum Facility Amount”:  With respect to the Advances, $150,000,000200,000,000, as may be increased pursuant to Section 2.1.
“Maximum Moody’s Rating Factor Test”:  A test that will be satisfied on any date of determination if the Weighted Average Moody’s Rating Factor of the Eligible Loans included in the Collateral (excluding Middle Market Loans) is less than or equal to 3550.
in any junior class of membership interests of the Borrower; (ii) any redemption, retirement, sinking fund or similar payment, purchase or other acquisition for value, direct or indirect, of any class of membership interests of the Borrower now or hereafter outstanding, and (iii) any payment made to redeem, purchase, repurchase or retire, or to obtain the surrender of, any outstanding warrants, options or other rights to acquire membership interests of the Borrower now or hereafter outstanding.
“Review Criteria”:  The meaning specified in Section 7.2(b)(i).

2
127235744v1

“Revolving Loan” :  Any Loan (other than a Delayed Draw Loan) that is a senior secured obligation (including funded and unfunded portions of revolving credit lines and letter of credit facilities, unfunded commitments under specific facilities and other similar loans and investments) that under the Underlying Instruments relating thereto may require one or more future advances to be made to the Obligor by the Borrower; provided that, any such Loan will be a Revolving Loan only until all commitments by the Borrower to make advances to the Obligor thereof expire, or are terminated, or are irrevocably reduced to zero.
“S&P”:  Standard & Poor’s Ratings Services, a Standard & Poor’s Financial Services LLC business, and any successor thereto.
“Sale Agreement”:  The Loan Sale Agreement, dated as of January 15, 2015, by and between the Seller and the Borrower, as the same has been amended, modified, restated, or supplemented from time to time.
“Sale Proceeds”:  With respect to any Loan, all proceeds received as a result of the sale of such Loan, net of all out-of-pocket expenses of the Borrower, the Collateral Manager and the Collateral Agent incurred in connection with any such sale.
“Scheduled Distribution”:  With respect to any Loan, for each due date, the scheduled payment of principal and/or interest due on such due date with respect to such Loan, determined in accordance with the applicable Underlying Instrument.
“Scheduled Payment”:  Each scheduled payment of principal and/or interest required to be made by an Obligor on the related Loan, as adjusted pursuant to the terms of the related Underlying Instruments, if applicable.
“Scheduled Reinvestment Period End Date”:  JulyNovember 18, 2023 (or, if such day is not a Business Day, the next succeeding Business Day).
“SEC”:    The Securities and Exchange Commission or any successor Governmental Authority.
“Second Delayed Funding Notice”:  The meaning specified in Section 2.2(e)(iii).
“Second Delayed Funding Notice Amount” The meaning specified in Section 2.2(e)(iii).
“Security Entitlement”:  The meaning specified in Section 8-102(a)(17) of the UCC.
“Seller:  The meaning specified in the Preamble.
“Senior Collateral Management Fee”:  The fee payable to the Collateral Manager on each Payment Date in arrears in respect of each Collection Period in accordance with the provisions of Sections 2.7(a) and (b) or Section 2.8, as applicable, which fee shall be equal to (i) the average daily Outstanding Balance of all Loans during the Collection Period related to such Payment Date multiplied by (ii) the Senior Collateral Management Fee Rate.

3
127235744v1

“Senior Collateral Management Fee Rate”:  0.50%per annum.
“Senior Debt/EBITDA Ratio”:  for any Obligor, the ratio of (x) senior Indebtedness (i.e., Indebtedness that is not subject to contractual or structural subordination) of such Obligor less unrestricted cash of such Obligor, to (y) EBITDA of such Obligor.
“Seventh Amendment Closing Date:”  November 18, 2021.
“Shareholders’ Equity”:  On any date of determination, the amount determined on a consolidated basis and without duplication, and in accordance with GAAP of shareholders’ equity for the Collateral Manager and its Subsidiaries at such date.
“Sixth Amendment Closing Date”:  July 2, 2021.
“SOFR”:  With respect to any Business Day, a rate per annum equal to the secured overnight financing rate for such Business Day published by the SOFR Administrator on the SOFR Administrator’s Website on the immediately succeeding Business Day.
“SOFR Administrator”:  The Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).
“SOFR Administrator’s Website”:  The website of the Federal Reserve Bank of New York, currently at http://www.newyorkfed.org, or any successor source for the secured overnight financing rate identified as such by the SOFR Administrator from time to time.
“Solvent”:  As to any Person at any time, having a state of affairs such that all of the following conditions are met:  (a) the fair value of the property of such Person is greater than the amount of such Person’s liabilities (including disputed, contingent and unliquidated liabilities) as such value is established and liabilities evaluated for purposes of Section 101(32) of the Bankruptcy Code; (b) the present fair saleable value of the property of such Person in an orderly liquidation of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts and other liabilities as they become absolute and matured; (c) such Person is able to realize upon its property and pay its debts and other liabilities (including disputed, contingent and unliquidated liabilities) as they mature in the normal course of business; (d) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability to pay as such debts and liabilities mature; and (e) such
4
127235744v1

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first above written.
BORROWER:
OCSL SENIOR FUNDING II LLC
By:  Oaktree Strategic Income Corporation
Its:  Designated Manager
By:  Oaktree Fund Advisors, LLC
Its:  Investment Advisor
By:                          
Name:
Title:
By:                          
Name:
Title:
[Signatures Continued on the Following Page]

Signature Page to LSA
127235744v1

Annex B
Commitments
						
	Lender	Commitment
	Citibank, N.A.	$150,000,000200,000,000

127235744v1Exhibit 10.1

 

CONSULTING AGREEMENT

 

THIS CONSULTING AGREEMENT
(including the exhibits attached hereto, this “Agreement”), effective as of February 7, 2022 (the “Effective
Date”), is entered into by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office at 75 Sidney
Street, Cambridge, MA 02139 (“Voyager”) and (ii) Alfred Sandrock, Jr., M.D., Ph.D., an individual residing at
                 (“Consultant”) (Voyager and Consultant, each a “Party,” and together, the “Parties”).

 

WHEREAS, Voyager is
a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological disease that is
developing one or more investigational new drugs (the “Business”); and

 

WHEREAS, Voyager desires to retain the consulting and/or advisory services of Consultant with respect to certain activities
as described in this Agreement, and Consultant is willing to so act.

 

NOW, THEREFORE,
Consultant and Voyager agree as follows:

 

		1.	Description of Services. Voyager hereby retains Consultant as a consultant to Voyager and
Consultant hereby agrees to use his/her best efforts to provide advice and assistance to Voyager in the area of Consultant’s expertise
related to the Business from time to time as requested by Voyager (the “Services”). In particular, the Services shall
include any specific activities described on the attached Description of Services Form attached hereto as Exhibit A (the “Statement
of Work”). Any changes to the Services (and any related compensation adjustments) must be agreed to in writing between Consultant
and Voyager prior to implementation of the changes.

 

		2.	Term & Termination. The term of this Agreement shall be the twelve (12) month contract
year commencing on the Effective Date, unless earlier terminated in accordance with this Agreement or extended by mutual written agreement
(the “Term”). Voyager may terminate this Agreement at any time without cause upon not less than ten (10) days’
prior written notice to Consultant. Consultant may terminate this Agreement at any time without cause upon not less than ten (10) days’
prior written notice to Voyager. Any expiration or termination of this Agreement shall be without prejudice to any obligation of either
party that has accrued prior to the effective date of expiration or termination. Upon expiration or termination of this Agreement, neither
Consultant nor Voyager will have any further obligations under this Agreement, except that (a) Consultant will terminate all Services
in progress in an orderly manner as soon as practicable and in accordance with a schedule agreed to by Voyager, unless Voyager specifies
in the notice of termination that Services in progress should be completed; (b) Consultant will deliver to Voyager all Work Product (defined
below) made through the expiration or termination of this Agreement; (c) Voyager will pay Consultant any monies due and owing Consultant
for Services performed and all authorized expenses actually incurred up to the time of termination or expiration; (d) Consultant will
immediately return to Voyager all Voyager Materials (defined below) and copies thereof provided to Consultant under this Agreement, subject
to Section 8; (e) the Receiving Party (as defined below) shall return to the Disclosing Party (as defined below) or destroy, at the Disclosing
Party’s sole discretion and cost, any and all Confidential Information (as defined below) in the Receiving Party’s possession
(including any and all paper or digital copies thereof) and, if applicable, provide a written certification to the Disclosing Party regarding
such destruction; provided, however, that the Receiving Party may retain (i) one (1) copy of Disclosing Party’s Confidential Information
in its confidential files, solely for the purpose of monitoring its surviving obligations and exercising its surviving granted or reserved
rights under this Agreement, and (ii) such additional copies of, or any computer records or files containing, the Disclosing Party’s
Confidential Information as have been created by the Receiving Party’s automatic archiving and back-up procedures, to the extent
created and retained in a manner consistent with the Receiving Party’s standard archiving and back-up procedures, but not for any
other use or purpose; and (f) the terms, conditions and obligations under Sections 2 and 4 through 18 will survive expiration or termination
of this Agreement.

 

    Page 1 of 12

     

    

 

		3.	Payment of Fees and Expenses. Voyager will pay Consultant a fee and expenses as set forth
in Exhibit A hereto.

 

Consultant agrees that the amounts payable
or otherwise provided by Voyager under this Agreement (i) represent the fair market value of the Services, (ii) have not been determined
in a manner that takes into account the volume or value of any referrals or business, and (iii) do not include any consideration to Consultant
in return for the purchasing, leasing, or ordering of any services other than the specific Services described in the Statement of Work.

 

Upon execution of
this Agreement, Consultant shall submit a W-9/W-8BEN/W-8ECI (as applicable) to Voyager’s Accounts Payable department at the address
above. Invoices will not be paid without Voyager’s receipt of Consultant’s W-9/W-8BEN/W-8ECI information.

 

		4.	Representations and Warranties.

 

		4.1.	Compliance with Laws. Consultant represents and warrants that Consultant will render Services
in compliance with (a) all applicable laws, statutes, directives, ordinances, codes, regulations, rules, by-laws, judgments, decrees,
and orders of any governmental or regulatory authority, department, body, agency, court, tribunal, bureau, commission, or other similar
body, whether federal, state, provincial, county, or municipal, in the United States and European Union (the “EU”)
(and/or in any other jurisdiction(s)), including but not limited to (i) those governing the purchase and sale of securities while in possession
of material, nonpublic information about Voyager, (ii) the federal and state anti-kickback and fraud and abuse laws and regulations and
laws governing payments to and relationships with healthcare professionals and other customers/potential customers, including 42 U.S.C.
 §1320a-7b(b) and 31 U.S. Code § 3729, (iii) the federal Food and Drug Administration laws, regulations and guidance, including
the federal Food, Drug and Cosmetic Act and the Prescription Drug Marketing Act, (iv) federal and state privacy and data protection laws,
including, but not limited to, the federal Health Insurance Portability and Accountability Act of 1996 and the Health Information Technology
for Economic and Clinical Health Act (“HIPAA”) and Chapter 93H of The Massachusetts General Laws and its implementing
regulations, 201 CMR 17.00, and Cal. Civ. Code § 1798.80-.84, and (v) any law or regulation requiring disclosure of any payments
made hereunder ((i)-(v), collectively, “Applicable Law”); (b) the highest professional standards; (c) any and all Voyager
policies and procedures; and (d) any other compliance requirements provided by Voyager. Without limiting Consultant’s obligation
to comply with all Applicable Law in providing Services, Consultant agrees to comply with (i) the United States Foreign Corrupt Practices
Act, as amended from time to time, and (ii) the OECD Anti-Bribery Convention with regard to Services, including not offering or giving
anything of value to a foreign public official in connection with the performance of the official’s duties or inducing an official
to use their position to influence any acts or decisions of any foreign, state or public international organization.

 

		4.2.	Absence of Debarment. Further, Consultant represents and warrants that Consultant and Consultant’s
affiliates and personnel have not been, and is not under consideration to be (a) debarred from providing services pursuant to Section
306 of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. § 335a; (b) excluded, debarred or suspended from, or otherwise
ineligible to participate in, any federal or state health care program or federal procurement or non-procurement programs (as that term
is defined in 42 U.S.C. §1320a-7b(f)); (c) disqualified by any government or regulatory agencies from performing specific services,
and is not subject to a pending disqualification proceeding; or (d) convicted of a criminal offense related to the provision of health
care items or services, or under investigation or subject to any such action that is pending. Consultant will notify Voyager immediately
in writing if Consultant, its affiliates, or any of their respective officers, directors or employees, as applicable, is subject to the
foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending, or to the best of Consultant’s
knowledge, is threatened.

 

    Page 2 of 12

     

    

 

		4.3.	Compliance with Obligations to Third Parties. Consultant represents and warrants to Voyager
that the terms of this Agreement and Consultant’s performance of the Services do not and will not conflict with any of Consultant’s
obligations to any third parties. Consultant represents that Consultant has not brought and will not bring with Consultant to Voyager
or use in the performance of the Services any equipment, funds, space, personnel, facilities, confidential information, trade secrets
or other resources of any third party which are not generally available to the public, unless Consultant has obtained written authorization
for their possession and use, nor will Consultant take any other action that would result in a third party, including without limitation,
an employer of Consultant, asserting ownership of, or other rights in, any Work Product, unless agreed upon in writing in advance by Voyager.
If Consultant is a faculty member at or employee of a university or hospital or another organization or Voyager (“Institution”),
Consultant represents and warrants that Consultant is not prohibited by any applicable policy of such Institution, including without limitation
any policy addressing conflicts of interest or intellectual property, from performing the Services or effectuating the assignment and/or
grant of rights and/or licenses to Voyager hereunder. To the extent Consultant is subject to any policy of Consultant’s employer
that requires approval of agreements governing external consulting services, Consultant represents that such approval has been given and
covenants that such approval will be obtained prior to entering into any amendment to this Agreement requiring such approval. Consultant
will notify Voyager immediately of any breach of this Section 4.3.

 

		4.4.	No Malicious Code. Consultant will provide all Work Product and/or Services free of any
security interests, claims, liens, or any other encumbrances whatsoever. Consultant will not knowingly introduce any malicious code into
the Work Product or otherwise cause any malicious code to interfere with or surreptitiously intercept or expropriate or damage Voyager's
systems. Consultant shall have appropriate security systems in place to protect against malicious code at all times during the Term, and
will test any Work Product prior to delivery to and/or use by Voyager to ensure that it is free of any malicious code.

 

		5.	Healthcare Compliance.

 

		5.1.	No Payments/Items of Value. Except as explicitly set forth in the Statement of Work or otherwise
approved in writing by Voyager, Consultant is prohibited from providing any payment, gift, remuneration or other transfer of value to
any healthcare organization or healthcare professional, patient organization or patient in connection with the provision of the Services
without prior written approval from Voyager and as specifically set forth in the Statement of Work. If such approval is provided by Voyager,
Consultant agrees to document all healthcare organization/healthcare professional identifier information requested by Voyager, as well
as provide documentation to support the amount/value of the payment, gift, remuneration or other transfer of value in accordance with
Section 5.2 of this Agreement.

 

		5.2.	Certain Disclosures and Transparency. Consultant acknowledges that Voyager and its affiliates
are required to abide by federal and state disclosure laws and certain transparency policies governing their activities including providing
reports to the government and to the public concerning financial or other relationships with healthcare providers. Consultant agrees that
Voyager and its affiliates may, in their sole discretion, disclose information about this Agreement and about Consultant’s Services
including those relating to healthcare providers and any compensation paid to healthcare providers pursuant to this Agreement. Consultant
agrees to promptly supply information reasonably requested by Voyager for the purposes of any such disclosure. To the extent that Consultant
is independently obligated to disclose specific information concerning Services relating to healthcare providers and compensation paid
to healthcare providers pursuant to this Agreement, Consultant will make timely and accurate required disclosures.

 

    Page 3 of 12

     

    

 

		5.3.	Adverse Event Reporting. If Consultant receives notice of any Adverse Events (as defined
below), other safety information (i.e. reports of misuse/abuse, overdose, off label use, medication errors including potential errors,
lack of efficacy, transmission of infectious agents, occupational exposure, and any drug exposure (maternal and paternal) during pregnancy
and/or breastfeeding) or complaints relating to any complaints associated with the use of any therapeutic product manufactured by or on
behalf of Voyager (collectively, “Safety Data”), Consultant will provide notice of such Safety Data to Voyager as soon
as possible, and in any event within one (1) business day of the time when Consultant first becomes aware of such Safety Data, in accordance
with Voyager's requirements. As used herein "Adverse Event" shall have the meaning set forth in 21 CFR 310.305 and 21
CFR 314.80.

 

		5.4.	Interactions with Healthcare Professionals. In the event that Consultant engages or interacts
with any healthcare professional or healthcare provider as part of the Services, Consultant shall comply with the terms and conditions
of this Agreement and the Statement of Work, any and all Voyager policies and procedures applicable to such interaction, and Applicable
Law. In addition, Consultant shall only use Voyager Materials specifically approved for use by Consultant for the Services, or such other
materials as Voyager may specifically approve for use by Consultant for the Services in writing in advance, in connection with such interactions.

 

		5.5.	Interactions with Patients and Patient Organizations. In the event that Consultant engages
or interacts with any patients or patient organizations as part of the Services, Consultant shall comply with the terms and conditions
of this Agreement and the Statement of Work, any and all Voyager policies and procedures applicable to such interaction, and Applicable
Law. In addition, Consultant shall only use Voyager Materials that are specifically approved for use by Consultant for the Services or
such other materials as Voyager may specifically approve for use by Consultant for the Services in writing in advance, in connection with
such interactions. Prior to engaging any patient in connection with the Services, Consultant shall obtain the patient's authorization
to Voyager's use of the Work Product and the Services as outlined in the Statement of Work and each such consent shall be prepared and
provided in accordance with Applicable Law.

 

		6.	Work Product.

 

		6.1.	Ownership. Consultant will promptly and fully disclose in confidence to Voyager any and
all inventions, discoveries, improvements, ideas, concepts, designs, processes, formulations, products, computer programs, works of authorship,
databases, mask works, trade secrets, know-how, information, data, documentation, reports, research, creations and other products (whether
or not patentable or subject to copyright or trade secret protection) arising from or made in the performance of the Services that are
related to the Business or that otherwise incorporate, reference, or rely upon Voyager’s Confidential Information, whether solely
by Consultant or jointly by Consultant and Voyager’s employees, contractors, and/or agents (collectively, the “Work Product”).
The Work Product shall constitute a “work made for hire” for the purposes of United States copyright laws, except to the extent
that it cannot legally constitute a “work made for hire.” Consultant hereby assigns to Voyager any and all of Consultant’s
rights, title and interest, throughout the world, in and to any and all Work Product that cannot legally constitute a “work made
for hire” for the purposes of United Sates copyright laws, except to the extent that such Work Product is not legally assignable.
To the extent that any such Work Product cannot by law constitute a “work made for hire” and is not otherwise legally assignable,
Consultant grants to Voyager an exclusive (even as between Voyager and Consultant), royalty-free, fully paid-up right and license to practice,
use, and exploit such Work Product for any and all purposes.

 

    Page 4 of 12

     

    

 

		6.2.	Representation and Warranty; Cooperation. Consultant represents and warrants that Consultant
has all rights in the Work Product required to effectuate the foregoing assignments and grants of licenses to Voyager of rights in such
Work Product. Consultant will execute all documents, and take any and all actions needed, all without further consideration, in order
to perfect Voyager’s rights in the Work Product (as set forth above). In the event that Consultant should fail or refuse to execute
such documents within a reasonable time, Consultant appoints Voyager as attorney to execute and deliver any such documents on Consultant’s
behalf. Consultant will keep and maintain adequate and current written records of all Work Product, and such records will be available
to and remain the sole property of Voyager at all times.

 

		6.3.	Consultant Property. Voyager acknowledges and agrees that, as of the Effective Date, Consultant
and Consultant’s affiliates possess certain templates, programs, methodologies, processes, technologies and/or other materials relating
directly to Consultant’s business that Consultant and its affiliates have developed, acquired, and/or licensed (a) independently
of this Agreement and (b) without the benefit of any information provided to Consultant by or on behalf of Voyager (collectively with
any and all associated intellectual property rights therein, the “Consultant Property”). Notwithstanding the foregoing,
Consultant will retain full ownership (as between the parties) of all rights, title, and interest, throughout the world, in and to such
Consultant Property, regardless of whether such Consultant Property is used in connection with Consultant’s performance of its obligations
under this Agreement. Notwithstanding the foregoing, Consultant hereby grants to Voyager and its affiliates a perpetual, non-exclusive,
fully paid-up worldwide, sublicensable license through multiple tiers, to use Consultant Property utilized by Consultant in the performance
of Services and incorporated into the Work Product for Voyager and its Affiliates to practice, use, and exploit the Work Product for any
and all purposes.

 

		7.	Confidentiality & Non-Use. 

 

		7.1.	Definition. “Confidential Information” means any and all scientific,
technical, financial, marketing, legal, regulatory, or business information, including trade secrets, in whatever form (written, oral
or visual) that is furnished or made available to a Party (the “Receiving Party”) by or on behalf of the other Party
(the “Disclosing Party”) and that (a) if in tangible form, is labeled in writing as proprietary or confidential; (b)
if in oral or visual form, is noted as proprietary or confidential at the time of disclosure or within fifteen (15) days thereafter; or
(c) a reasonable person in the life sciences industry would understand to be confidential or proprietary based on its nature or the circumstances
of its disclosure. For the avoidance of doubt, (y) Voyager’s Confidential Information shall include (i) all Work Product, (ii) any
and all Voyager Materials (including any and all information contained in or comprising the Voyager Materials), and (iii) all confidential
and proprietary data, trade secrets, business plans, and other information of a confidential or proprietary nature in written, electronic
or other media, belonging to Voyager or its subsidiaries or third parties with whom Voyager may have business dealings, disclosed or otherwise
made available to Consultant by Voyager or on behalf of Voyager; in each case of (i)-(iii), excluding any Consultant Property; and (z)
Consultant’s Confidential Information includes all confidential and proprietary data, trade secrets, business plans, and other information
of a confidential or proprietary nature in written, electronic or other media contained or embodied in the Consultant Property.

 

    Page 5 of 12

     

    

 

		7.2.	Obligations. During the Term and for a period of ten (10) years following the expiration
or termination of this Agreement, subject to Section 7.3, the Receiving Party agrees to (a) hold the Disclosing Party’s Confidential
Information in confidence; (b) exercise reasonable precautions to physically protect the integrity and confidentiality of the Disclosing
Party’s Confidential Information; (c) not disclose any of the Disclosing Party’s Confidential Information to any third party
without the prior written consent of the Disclosing Party; (d) not use the Disclosing Party’s Confidential Information for any purpose
except as may be necessary for the Receiving Party to perform its obligations and exercise its granted or reserved rights under this Agreement
(including, in the case of Consultant, in the ordinary course of performing Services) without the prior written consent of the Disclosing
Party; (e) treat the Disclosing Party’s Confidential Information with no less than a reasonable degree of care; and (f) reproduce
the Disclosing Party’s Confidential Information solely to the extent necessary for the Receiving Party to perform its obligations
and exercise its granted or reserved rights under this Agreement (including, in the case of Consultant, to provide the Services), with
all such reproductions being considered the Disclosing Party’s Confidential Information. Notwithstanding the foregoing, the Receiving
Party’s non-disclosure and non-use obligations set forth in this Section 7.2 with respect to trade secrets included in the Disclosing
Party’s Confidential Information will continue for as long as such Confidential Information continues to constitute trade secret
under Applicable Law. The Receiving Party may disclose the Disclosing Party’s Confidential Information solely to its employees,
contractors, or agents (collectively, “Representatives”) on a need-to-know basis, provided that any such Representatives
are bound by written obligations of confidentiality at least as restrictive as those set forth herein, and Receiving Party remains liable
for the compliance of such Representatives. Notwithstanding the foregoing, the Receiving Party’s obligations of non-disclosure and
non-use under this Section 7.2 will not apply to any portion of the Disclosing Party’s Confidential Information that the Receiving
Party establishes by competent proof: (v) was in the public domain at the time of disclosure through no wrongful act on the part of the
Receiving Party; (w) after disclosure, becomes part of the public domain by publication or otherwise, except by a wrongful act on the
part of the Receiving Party; (x) was known to the Receiving Party at the time of disclosure by the Disclosing Party other than as a result
of the Receiving Party’s breach of any legal obligation; (y) becomes known to the Receiving Party on a non-confidential basis through
disclosure by sources other than the Disclosing Party having the legal right to disclose such Confidential Information; or (z) is independently
developed by the Receiving Party without reference to or reliance upon the Disclosing Party’s Confidential Information. The Receiving
Party may disclose the Disclosing Party’s Confidential Information to a governmental authority or by order of a court of competent
jurisdiction only if required and provided that the disclosure is subject to all applicable governmental or judicial protection available
for like material and, to the extent permitted under Applicable Law, reasonable advance notice is given to the Disclosing Party.

 

		7.3.	Permitted Disclosures. The Receiving Party understands and acknowledges that nothing in
this Agreement or elsewhere prohibits the Receiving Party from communicating with government agencies about possible violations of federal,
state, or local laws or otherwise providing information to government agencies, filing a complaint with government agencies, or participating
in government agency investigations or proceedings. The Receiving Party understands that the Receiving Party is not required to notify
the Disclosing Party of any such communications; provided, however, that nothing herein authorizes the disclosure of information obtained
by the Receiving Party through a communication that was subject to the attorney-client privilege of the Disclosing Party. Further, notwithstanding
the Receiving Party’s non-disclosure and non-use obligations under Section 7.2, the Receiving Party understands that the Receiving
Party is hereby advised as follows pursuant to the Defend Trade Secrets Act: An individual shall not be held criminally or civilly liable
under any Federal or State trade secret law for the disclosure of a trade secret that is made in confidence to a Federal, State, or local
government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected
violation of law, or is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret
to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing
the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.

 

    Page 6 of 12

     

    

 

		7.4.	Personal Identifiable Information. Notwithstanding anything to the contrary in this Agreement,
Consultant will not disclose to any third party nor use any protected health information, personal data, patient data, or biological samples
of subjects enrolled in clinical studies that are the subject of the Services (collectively, “Personal Identifiable Information”)
except as expressly required by Voyager and as long as such disclosure and use is in compliance with Applicable Law; and (b) such restrictions
on the disclosure and use of Personal Identifiable Information will remain in place for as long as such restrictions are required under
Applicable Law. Voyager’s use and disclosure of Personal Identifiable Information will be in accordance with Applicable Law and
the relevant consent documents. In the event that Consultant, in the course of providing the Services to Voyager, receives, stores, maintains,
processes or otherwise has access to Personal Identifiable Information (including, but not limited to, an individual’s name and
social security number, driver’s license number or financial number) then Consultant shall safeguard this information in accordance
with Applicable Law, and to the extent that Consultant experiences a security breach for information generated in connection with this
Agreement, Consultant shall notify Voyager thereof in writing within twenty-four (24) hours of discovering such security breach.

 

		8.	Voyager Materials and Facilities. Voyager shall retain exclusive ownership (as between Voyager
and Consultant) of all rights, title, and interest in and to any and all documents, data, information, records, materials, apparatus,
equipment and other physical property furnished or made available by or on behalf of Voyager to Consultant in connection with this Agreement
(collectively with all associated intellectual property rights therein, the “Voyager Materials”). Except as is expressly
set forth herein, Consultant shall have no rights, title, or interest in or to any Voyager Materials, whether by implication, estoppel,
or otherwise. Consultant shall promptly return any Voyager Materials to Voyager upon Voyager’s request. In any event, Consultant
shall return and deliver all Voyager Materials, including any copies thereof, upon termination or expiration of this Agreement, irrespective
of the reason for such termination. Consultant will use Voyager Materials only as necessary to perform the Services and will not transfer
or make available to any third party the Voyager Materials without the express prior written consent of Voyager. Consultant recognizes
that Voyager’s facilities are private and Consultant will abide by Voyager's security requirements and conditions for access and
usage and agrees that only those subjects, areas and programs designated by Voyager as necessary to fulfill Voyager’s requirements
will be accessed and/or perused by Consultant. In no event will any Confidential Information of Voyager, programs or other information
be copied or removed by Consultant without Voyager's express written approval. Notwithstanding the foregoing, Consultant may retain any
communication between Consultant and Voyager with respect to payment of fees and expenses and a copy of this Agreement, or amendments
hereto, or other document related to enforcement of the obligations in this Agreement, subject to nondisclosure and nonuse obligations
set forth in this Agreement except that Consultant may share such documents with his financial advisors, accountants, and legal counsel
as necessary.

 

		9.	Publication; Publicity. Work Product may not be published or referred to, in whole or in
part, by Consultant without the prior express written consent of Voyager. Consultant shall not use the name, logo, trade name, service
mark, or trademark, or any simulation, abbreviation, or adaptation of same, or the name of Voyager or its subsidiaries for publicity,
promotion, or similar non-regulatory uses without Voyager’s prior written consent.

 

		10.	Recordings and Images.  During the term of this Agreement, Consultant hereby consents
to Voyager or any designee, employee or agent of Voyager, recording, in any medium and by any method (including, but not limited to, photographing,
filming, audio-recording, transcribing, and/or video-recording), the testimonial(s), presentation(s) and/or interview(s) of Consultant
created in connection with this Agreement (collectively “Recordings”).  Consultant acknowledges and agrees that
Consultant provides these Recordings free of charge without any obligation of Voyager to provide consideration for such Recordings. 
Consultant by signing this Agreement hereby irrevocably grants to Voyager and its successors, assigns, and licensees the perpetual right
to use Consultant’s image, name, likeness and sound of Consultant’s voice as recorded in such Recordings.  Consultant
understands and agrees that such Recordings may be edited, copied, exhibited (including, but not limited to, exhibit or display via the
Internet or other electronic means), published or distributed for any lawful purpose (including, but not limited to educational, informational,
promotional and advertising materials).   Consultant waives the right to royalties or other compensation arising from or related
to the use of such Recordings or Consultant’s image as contained in such Recordings.  There is no geographic limitation on
where these Recordings and the materials derived using these Recordings may be distributed.  Consultant understands and agrees that
Voyager is and shall be the exclusive owner of any and all right, title, and interest, including copyright, in and to any and all Recordings
and materials derived from such Recordings that are created under this Agreement.  Consultant hereby releases any and all claims
Consultant may have now or in the future for invasion of privacy or right of publicity against Voyager, or any person or organization
collecting this material on behalf of Voyager with respect to the collection of such material, and with respect to the use, distribution
or derivation of materials from such Recordings so long as the distribution of such Recordings is for reasonable and legitimate business
purposes as determined by Voyager and are distributed in a responsible manner in accordance with general industry practices.

 

    Page 7 of 12

     

    

 

		11.	Insurance. Consultant shall maintain such insurance as shall be reasonably necessary
to insure itself against any claim or claims for damages arising out of the Services or this Agreement. Consultant shall provide
evidence of such coverage to Voyager upon request.

 

		12.	Non-Solicitation; Certain Other Conflicts of Interest; Trading in Voyager Securities.

 

		12.1.	Non-Solicitation of Customers, Employees and Contractors. In order to protect Voyager’s
Confidential Information and goodwill, during the Term of this Agreement and for a period of one (1) year following the termination of
or expiration of this Agreement for any reason (the “Restricted Period”), Consultant will not, directly or indirectly,
in any manner, other than for the benefit of Voyager:

 

		(a)	solicit, divert, or take away, any business from or with any of the customers or prospective customers
of Voyager or any of its vendors, collaborators or suppliers with whom Consultant was actively involved in the course of providing Services;

 

		(b)	(i) solicit for employment or employ any individual who is currently employed by Voyager or engaged by
Voyager as a consultant, or who was employed by Voyager or engaged by Voyager as a consultant within the previous twelve (12) months (each,
a “Covered Individual”), (ii) induce, encourage, entice, or attempt to solicit any such Covered Individual to leave
Voyager for any reason, or (iii) otherwise participate in or facilitate the hire, directly or through another entity, of any such Covered
Individual. Notwithstanding the foregoing, it will not be a violation of this provision if (A) a third party with whom Consultant has
a relationship hires or engages a Covered Individual without Consultant’s involvement; or (B) Consultant or a third party with whom
Consultant has any relationship hires or engages a Covered Individual based on the Covered Individual’s responding to a general
job advertisement or listing without any solicitation by Consultant; or

 

		(c)	recommend to any third party or person that they employ or solicit for employment or form an association
with a Covered Individual, unless such recommendation is made at the express request of a Covered Individual and is requested by the Covered
Individual as a reference supporting an offer of employment that has been previously received by the Covered Individual.

 

Consultant
acknowledges and agrees that if Consultant violates any of the provisions of this Section 12.1, and to the extent permitted by
law, the running of the Restricted Period will be extended by the time during which Consultant engages in such violation(s).

 

		12.2.	Certain Other Conflicts of Interest. Consultant represents that, except as disclosed in
writing to Voyager, Consultant: (a) does not own directly or indirectly five percent (5%) or more of the stock or other equity securities
of any entity which is a Competitive Business or a current or potential customer or supplier of Voyager; (b) is not aware of any legal
proceedings pending or threatened against Consultant, or any reasonable basis for such proceedings, which (i) would conflict with Consultant’s
obligations hereunder or question the validity of this Agreement; or (ii) may materially or adversely affect the business or prospects
of Voyager; and (c) is not aware of any fact concerning Consultant (either professionally or personally) which may materially or adversely
affect the business or prospects of Voyager.

 

    Page 8 of 12

     

    

 

		12.3.	Trading in Voyager Securities. Consultant is aware that the United States and other applicable
securities laws prohibit any person who has material, non-public information about a company from purchasing or selling securities of
such company or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that
such person is likely to purchase or sell such securities. Consultant may gain access to information in connection with the provision
of Services that could potentially subject Consultant to insider trading liability (as defined under the US federal securities laws and
regulations adopted by the United States Securities and Exchange Commission) in connection with trading in Voyager securities. Consultant
shall comply with all relevant laws respecting any trading in Voyager securities.

 

		13.	Independent Contractor Relationship. Nothing contained in this Agreement shall be deemed
to establish an employment relationship between Voyager and Consultant, it being the intent of the parties to establish an independent
contractor relationship, nor shall Consultant have authority to bind Voyager in any manner whatsoever by reason of this Agreement. Consultant
shall at all times while on Voyager premises observe all security and safety policies of Voyager. Consultant is excluded from participating
in any fringe benefit plans or programs as a result of the performance of the Services, without regard to Consultant’s independent
contractor status, including, but not limited to, health, sickness, accident or dental coverage, life insurance, disability benefits,
accidental death and dismemberment coverage, unemployment insurance coverage, workers’ compensation coverage, 401(k) benefit(s),
and any other benefits provided by Voyager to its employees. Consultant agrees, as an independent contractor, that Consultant is not entitled
to unemployment benefits in the event this Agreement terminates, or workers’ compensation benefits in the event that Consultant
is injured in any manner or becomes ill while performing the Services under this Agreement. Because Consultant is an independent contractor,
Voyager will not make any withholdings, deductions, or contributions (e.g., social security, unemployment insurance, disability insurance)
from Consultant’s fees, and will report Consultant’s fees and other payments to Consultant on a 1099 form. Consultant shall
bear sole responsibility for paying and reporting its own applicable federal and state income taxes, social security taxes, unemployment
insurance, workers’ compensation, and health or disability insurance, retirement benefits, and other welfare or pension benefits,
if any, and shall indemnify and hold Voyager harmless from and against any liability with respect thereto.

 

		14.	Notices. All notices required or permitted under this Agreement must be in writing. Any
notice given under this Agreement shall be deemed delivered when delivered by hand, by certified mail, by air courier or via facsimile
to the parties at their respective addresses set forth above for Consultant and below for Voyager or at such other address as either party
may provide to the other in writing from time to time. Communications and notices to Voyager will be sent to:

 

Voyager Therapeutics, Inc.

Attn: President & CEO

75 Sidney Street

Cambridge, MA 02139

U.S.A.

 

With a copy to (which shall not constitute
notice):

Voyager Therapeutics, Inc.

Attn: General Counsel

75 Sidney Street

Cambridge, MA 02139

U.S.A

 

Notices will be effective upon receipt
or at a later date stated in the notice.

 

		15.	Assignment. The rights and obligations of the parties hereunder shall inure to the benefit
of, and shall be binding upon their respective successors and assigns. This Agreement may not be assigned by Consultant, and Consultant’s
obligations under this Agreement may not be subcontracted or delegated by Consultant, without the prior written consent of Voyager. For
clarity, this Agreement may be assigned by Voyager with prompt notice of such assignment to Consultant.

 

    Page 9 of 12

     

    

 

		16.	Collaboration with Neurocrine.  Consultant acknowledges and agrees that: (a) Voyager
and Neurocrine Biosciences, Inc., a Delaware corporation with principal offices located at 12780 El Camino Real, San Diego, CA 92130 (“Neurocrine”)
are parties to a certain Collaboration and License Agreement, effective January 28, 2019, by and between Voyager and Neurocrine, as amended
from time to time, (the “Neurocrine CLA”); (b) during the term of the Neurocrine CLA, Neurocrine will have full access
and use of any and all Services and Work Product relating to a Collaboration Program; (c) during the term of the Neurocrine CLA, Neurocrine
shall have the right to enforce any of the provisions of this Agreement concerning a Collaboration Program as a third-party beneficiary;
and (d) except for Neurocrine, there are no third-party beneficiaries with any rights to enforce any of the provisions of this Agreement
concerning a Collaboration Program. For the purposes of this Section 16, “Collaboration Program” shall mean any of
Voyager’s programs and/or activities relating to the development, production, sale, or commercialization of any products, investigational
compounds, or processes that involve gene therapy for central nervous system disorders relating to: (y) Voyager’s Friedreich’s
Ataxia program as it pertains to the Neurocrine CLA; or (z) either of the two (2) yet to-be-named additional Voyager compounds/targets/programs
pertaining to the Neurocrine CLA, subject to Voyager’s prior written notice to Consultant of each such compound/target/programs.

 

		17.	Specific Enforcement. Each Party acknowledges that any breach by the other Party of its
obligations under Sections 4 through 9 and Section 12 of this Agreement may result in serious and irreparable injury to the non-breaching
Party for which the non-breaching Party cannot be adequately compensated by monetary damages alone. Each Party agrees, therefore, that,
in addition to any other remedy the non-breaching Party may have, the non-breaching Party shall be entitled to enforce the specific performance
of this Agreement by the breaching Party and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without
the necessity of proving actual damages or posting a bond.

 

		18.	Prior Agreements; Governing Law; Severability; Amendment. This Agreement embodies the entire
understanding between the parties with respect to the subject matter of this Agreement and supersedes any prior or contemporaneous agreements
with respect to the subject matter of this Agreement. This Agreement shall be governed by and construed in accordance with the laws of
the Commonwealth of Massachusetts, without regard to any choice of law principle that would dictate the application of the law of another
jurisdiction, and Consultant submits to the jurisdiction and agrees to the proper venue of all state and federal courts located within
the Commonwealth of Massachusetts. Each provision in this Agreement is independent and severable from the others, and no provision will
be rendered unenforceable because any other provision is found by a proper authority to be invalid or unenforceable in whole or in part.
If any provision of this Agreement is found by such an authority to be invalid or unenforceable in whole or in part, such provision shall
be changed and interpreted so as to best accomplish the objectives of such unenforceable or invalid provision and the intent of the parties,
within the limits of Applicable Law. This Agreement may be executed in one or more counterparts, each of which will be deemed an original,
and all of which together will be deemed to be one and the same instrument. A facsimile or electronic copy of this Agreement, including
the signature pages, will be deemed an original. This Agreement may not be amended, and its terms may not be waived, except pursuant to
a written amendment or waiver signed by both parties.

 

 

[Remainder of this page is intentionally left blank]

 

    Page 10 of 12

     

    

 

SIGNATURE PAGE TO

CONSULTING AGREEMENT

 

IN WITNESS WHEREOF, the parties hereto have entered
into this Agreement intending it to be effective as of the Effective Date.

 

	VOYAGER:	 
	 	 
	 	VOYAGER THERAPEUTICS, INC.	 
	 	 
	 	By:	/s/ Michael Higgins	 
	 	Name:	Michael Higgins	 
	 	Title:	Chairman of the Board of Directors, Interim President & Chief Executive Officer	 
	 	 
	CONSULTANT:	 
	 	 
	 	ALFRED SANDROCK, JR., M.D., PH.D.	 
	 	 	 
	 	By:	/s/ Alfred Sandrock, Jr.	 
	 	Name:	Alfred Sandrock, Jr., M.D., Ph.D.	 

 

 

    Page 11 of 12

     

    

 

EXHIBIT A

 

STATEMENT OF WORK

 

Consulting Agreement Between Voyager Therapeutics,
Inc. (“Voyager”) and

Consultant 

 

		1.	Services:

 

Consultant will
provide the following advisory and consulting services concerning strategic planning, operations, and management (the “Services”).
Consultant will provide up to 2.5 days of Services per week during the Term.

 

Consultant will provide Services on a
schedule and at a location or locations as appropriate for the effective performance of the Services. In addition, Consultant will be
available for a reasonable number of telephone and/or written consultations.

 

		2.	Compensation:

 

Fees:
Voyager will pay Consultant a retainer of thirty thousand United States Dollars ($30,000 USD) per month during the Term, payable no later
than the 10th of each month for which Services are to be provided.

 

Expenses:
Voyager will reimburse Consultant for any pre-approved expenses actually incurred by Consultant in connection with the provision of Services.
Requests for reimbursement will be in a form reasonably acceptable to Voyager, will include supporting documentation and will accompany
Consultant’s invoices.

 

Invoicing:
No later than the last day of each calendar month, Consultant will invoice Voyager for expenses incurred during the preceding month. Invoices
should reference this Agreement and the PO number provided by Voyager (if applicable) and should be submitted to Voyager Accounts Payable
by email to: ap@vygr.com. Invoices will contain such detail as Voyager may reasonably require and will be payable in U.S. Dollars. Undisputed
payments will be made by Voyager within thirty (30) days after Voyager’s receipt of Consultant’s invoice, request for reimbursement
and all supporting documentation.

 

    Page 12 of 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]